Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 51.95 USD 1.94% Market Closed
Market Cap: 105.8B USD

Intrinsic Value

The intrinsic value of one BMY stock under the Base Case scenario is 72.37 USD. Compared to the current market price of 51.95 USD, Bristol-Myers Squibb Co is Undervalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BMY Intrinsic Value
72.37 USD
Undervaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Bristol-Myers Squibb Co

What is Valuation History?
Ask AI Assistant
What other research platforms think about BMY?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BMY valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Bristol-Myers Squibb Co.

Explain Valuation
Compare BMY to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Heightened patent-expiration risk and revenue concentration around key drugs like Revlimid and Eliquis could sharply reduce Bristol-Myers Squibb’s cash flows, limiting its ability to fund pipeline development.

Rising competition in the immuno-oncology space, especially from Merck’s Keytruda and Roche’s Tecentriq, threatens market share and pricing power for BMY’s flagship therapies such as Opdivo.

The company’s ambitious R&D strategy, combined with recent large-scale acquisitions, presents integration and execution risks that could weigh on profitability if pipeline candidates fail to deliver expected returns.

Bull Theses

Bristol-Myers Squibb holds a leading position in immuno-oncology with proven blockbusters like Opdivo and Yervoy, providing a strong base of recurring revenue and brand recognition.

The combined portfolios from Celgene and MyoKardia acquisitions bolster BMY’s pipeline in oncology and cardiovascular treatments, diversifying revenue streams and driving potential long-term growth.

Robust free cash flow and a strong balance sheet allow for continued investment in novel therapies, strategic partnerships, and share repurchases, signaling potential for sustained shareholder returns.

Show More Less
How do you feel about BMY?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bristol-Myers Squibb Co

Current Assets 35.6B
Cash & Short-Term Investments 16.5B
Receivables 14.6B
Other Current Assets 4.5B
Non-Current Assets 61.3B
Long-Term Investments 2.3B
PP&E 9B
Intangibles 42.2B
Other Non-Current Assets 7.8B
Current Liabilities 28.1B
Accounts Payable 4.3B
Accrued Liabilities 15B
Short-Term Debt 261m
Other Current Liabilities 8.6B
Non-Current Liabilities 50.2B
Long-Term Debt 44.5B
Other Non-Current Liabilities 5.7B
Efficiency

Free Cash Flow Analysis
Bristol-Myers Squibb Co

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Bristol-Myers Squibb Co

Revenue
48B USD
Cost of Revenue
-12.9B USD
Gross Profit
35.1B USD
Operating Expenses
-19B USD
Operating Income
16.1B USD
Other Expenses
-10.1B USD
Net Income
6B USD
Fundamental Scores

BMY Profitability Score
Profitability Due Diligence

Bristol-Myers Squibb Co's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Exceptional Operating Margin
Exceptional Gross Margin
ROE is Increasing
60/100
Profitability
Score

Bristol-Myers Squibb Co's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

BMY Solvency Score
Solvency Due Diligence

Bristol-Myers Squibb Co's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average Altman Z-Score
40/100
Solvency
Score

Bristol-Myers Squibb Co's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BMY Price Targets Summary
Bristol-Myers Squibb Co

Wall Street analysts forecast BMY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMY is 53.02 USD with a low forecast of 33.43 USD and a high forecast of 71.4 USD.

Lowest
Price Target
33.43 USD
36% Downside
Average
Price Target
53.02 USD
2% Upside
Highest
Price Target
71.4 USD
37% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BMY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

BMY Insider Trading
Buy and sell transactions by insiders

BMY News

Other Videos
What is the Intrinsic Value of one BMY stock?

The intrinsic value of one BMY stock under the Base Case scenario is 72.37 USD.

Is BMY stock undervalued or overvalued?

Compared to the current market price of 51.95 USD, Bristol-Myers Squibb Co is Undervalued by 28%.

Back to Top